Loading...
XNAS
GRAL
Market cap3.43bUSD
Aug 28, Last price  
80.00USD
Name

Grail Inc

Chart & performance

D1W1MN
XNAS:GRAL chart
P/E
P/S
23.33
EPS
Div yield, %
Shrs. gr., 5y
-21.55%
Rev. gr., 5y
%
Revenues
Net income
CFO

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
IPO date
Jun 12, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show